Stock Screener App

Frei -

Installieren

19.21

2.88% -0.57

after-market

Handel nachbörslich: 19.21

Bicara Therapeutics Inc (BCAX)

Überblick Nachrichten Preisverlauf Forum Prognose

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com South Africa

Bicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - The Chronicle-Journal

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Analyzing a 52.89% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing - Kalkine Media

Bicara interim CEO sells 17,500 shares after option exercise - Stock Titan

BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan

Cantor Fitzgerald reiterates Overweight on Bicara stock - Investing.com India

JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - moomoo.com

BCAX 424B FilingsBicara Therapeutics Inc. SEC 424B - Stock Titan

BCAX 8-K FilingsBicara Therapeutics Inc. SEC 8-K - Stock Titan

Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Price, News & Analysis - Kalkine

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Bicara Therapeutics Announces Inducement Gran - Moomoo

Boston biotech Bicara signs sublease for Wayfair space - The Business Journals

Bicara (BCAX) Financial Results: Reported EPS Tops Expectations in the Latest Session; Share Move: The Stock Records a 0.50% Decrease in the Current UpdateDividend Cut Risk - vinanet.vn

How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors - webull.com

Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com

Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada

Jennifer Larson Net Worth (2026) - GuruFocus

Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat

BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo

Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo

Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance

BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget

Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance

BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India

Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm

SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat

BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView

Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat

Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan

Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board - Endpoints News

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX - MarketBeat

Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45 - Moomoo

Janus Henderson Group (BCAX) reports 3.17M Bicara Therapeutics shares in 13G/A - Stock Titan

Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL) - The Globe and Mail

Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX) - Yahoo Finance

Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results - webull.com

Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail

Bicara Therapeutics CEO Claire Mazumdar Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media

Bicara Therapeutics CFO Ivan Hyep Executes Sale of 12,500 Shares via 10b5-1 Plan - Kalkine Media

Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat

Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock - MarketBeat

Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat

Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing - marketscreener.com

Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing - marketscreener.com

Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan - Stock Titan

Bicara Therapeutics (BCAX) CEO exercises 10K options and sells 10K shares under plan - Stock Titan

Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares - Stock Titan

INSM

$117.83

3.06%

ROIV

$35.80

0.91%

RPRX

$58.21

0.14%

ALNY

$255.96

2.55%

ONC

$360.85

0.24%

RVMD

$204.97

2.56%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters